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Abstract
Background: Numerous studies have demonstrated the efficacy of creatine supplementation for improvements in
exercise performance. Few studies, however, have examined the effects of phosphocreatine supplementation on
exercise performance. Furthermore, while polyphenols have antioxidant and anti-inflammatory properties, little is
known regarding the influence of polyphenol supplementation on muscular strength, power, and endurance. Thus,
the purpose of the present study was to compare the effects of 28 days of supplementation with phosphocreatine
disodium salts plus blueberry extract (PCDSB), creatine monohydrate (CM), and placebo on measures of muscular
strength, power, and endurance.
Methods: Thirty-three men were randomly assigned to consume either PCDSB, CM, or placebo for 28 days. Peak
torque (PT), average power (AP), and percent decline for peak torque (PT%) and average power (AP%) were
assessed from a fatigue test consisting of 50 maximal, unilateral, isokinetic leg extensions at 180°·s− 1 before and
after the 28 days of supplementation. Individual responses were assessed to examine the proportion of subjects
that exceeded a minimal important difference (MID).
Results: The results demonstrated significant (p < 0.05) improvements in PT for the PCDSB and CM groups from
pre- (99.90 ± 22.47 N·m and 99.95 ± 22.50 N·m, respectively) to post-supplementation (119.22 ± 29.87 N·m and
111.97 ± 24.50 N·m, respectively), but no significant (p = 0.112) change for the placebo group. The PCDSB and CM
groups also exhibited significant improvements in AP from pre- (140.18 ± 32.08 W and 143.42 ± 33.84 W,
respectively) to post-supplementation (170.12 ± 42.68 W and 159.78 ± 31.20 W, respectively), but no significant (p =
0.279) change for the placebo group. A significantly (p < 0.05) greater proportion of subjects in the PCDSB group
exceeded the MID for PT compared to the placebo group, but there were no significant (p > 0.05) differences in the
proportion of subjects exceeding the MID between the CM and placebo groups or between the CM and PCDSB
groups.
© The Author(s). 2021 Open Access This article is licensed under a Creative Commons Attribution 4.0 International License,
which permits use, sharing, adaptation, distribution and reproduction in any medium or format, as long as you give
appropriate credit to the original author(s) and the source, provide a link to the Creative Commons licence, and indicate if
changes were made. The images or other third party material in this article are included in the article's Creative Commons
licence, unless indicated otherwise in a credit line to the material. If material is not included in the article's Creative Commons
licence and your intended use is not permitted by statutory regulation or exceeds the permitted use, you will need to obtain
permission directly from the copyright holder. To view a copy of this licence, visit http://creativecommons.org/licenses/by/4.0/.
The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the
data made available in this article, unless otherwise stated in a credit line to the data.
* Correspondence: janders@huskers.unl.edu
1Department of Nutrition and Human Sciences, University of
Nebraska-Lincoln, Lincoln, NE 68510, USA
Full list of author information is available at the end of the article
Anders et al. Journal of the International Society of Sports Nutrition           (2021) 18:60 
https://doi.org/10.1186/s12970-021-00456-y
Conclusions: These findings indicated that for the group mean responses, 28 days of supplementation with both
PCDSB and CM resulted in increases in PT and AP. The PCDSB, however, may have an advantage over CM when
compared to the placebo group for the proportion of individuals that respond favorably to supplementation with
meaningful increases in muscular strength.
Keywords: Phosphocreatine, Blueberry, Polyphenols, Creatine monohydrate, Antioxidant, Isokinetic, Strength, Power,
Muscular endurance
Background
Creatine is a naturally occurring, nitrogenous compound
synthesized from arginine, glycine, and methionine that
can be produced endogenously by the liver, kidneys, and
pancreas, or obtained exogenously from dietary sources
such as red meats and fish [1–3]. Creatine is primarily dis-
tributed in skeletal muscle as either free creatine or
phosphocreatine [1, 4], where it functions as part of the
phosphagen energy system to provide energy and facilitate
ATP resynthesis via creatine kinase, in particular during
very high intensity exercise [2, 5]. Creatine absorption is
mediated by sodium and chloride-dependent transporters
where it is first absorbed in small intestines, then distrib-
uted throughout the body, where skeletal muscle serves as
a primary reserve [6, 7]. Exogenous creatine supplementa-
tion has been demonstrated to enhance intramuscular
stores by 20–40% and elicit ergogenic effects [1–3, 8].
A 28–30 day creatine supplementation period has been
shown to increase muscle creatine concentrations and
improve exercise performance [9–13]. Short duration
creatine loading phases (approximately 20 g of creatine
for 5–7 days) have also been implemented, however, it
has been demonstrated that 28 days of 3.0 g·d− 1 of creat-
ine monohydrate supplementation resulted in approxi-
mately the same 20% increase in total muscle creatine
[14]. Thus, 28 days of creatine supplementation is suffi-
cient to examine the potential ergogenic effects.
Creatine monohydrate (CM) is the most common delivery
form due to its high bioavailability and stability. However,
numerous forms of creatine exist in the nutritional supple-
ment market, such as creatine citrate, creatine hydrochlor-
ide, creatine pyruvate, creatine malate, and sodium creatine
phosphate [2, 15]. Furthermore, the formulation of a salt-
creatine complex functions to improve solubility in solution
due to the reduction in pH from the salt’s acid moiety, as
well as functioning to improve the stability of creatine in
solution where a low pH reduces intramolecular cyclization
that results in the degradation of creatine to creatinine [15].
Recent studies have demonstrated that these alternative
formulations may improve bioavailability and exercise per-
formance [9, 16]. Thus, while CM has been well established
as an effective delivery form to elicit improvements in exer-
cise performance, more research is warranted to examine
whether other creatine formulations may exhibit similar, or
potentially greater overall improvements in performance.
During exercise, the production of reactive oxygen spe-
cies in the muscle has been associated with the develop-
ment of muscular fatigue due to its detrimental effects on
excitation-contraction coupling and gene expression, as
well as general oxidative stress on intramuscular lipids,
proteins, and DNA [17, 18]. It has been demonstrated that
supplementation with antioxidants may attenuate the
deleterious effects of reactive oxygen species produced
from exercise, potentially resulting in faster muscle recov-
ery [18–20]. Polyphenols are a family of plant-derived
metabolites including stilbenes, lignans, phenolic acids,
and flavonoids that function as antioxidants [20]. While
evidence suggests polyphenol supplementation may
improve exercise performance [19, 21], the efficacy of
polyphenol supplementation on measures of muscular
strength, power, and endurance remains to be fully eluci-
dated. Therefore, the purpose of the present study was to
compare the effects of 28 days of supplementation with a
blend of phosphocreatine disodium salts plus blueberry
extract (PCDSB), CM, and placebo on measures of
muscular strength, power, and endurance. Based on the
findings of previous studies [11, 22, 23], we hypothesized
that supplementation with PCDSB would exhibit greater
improvements in muscular strength, power, and endurance
than supplementation with CM or placebo.
Methods
Experimental approach
The present study implemented a double-blind, placebo-
controlled, parallel design. The study consisted of a
familiarization visit, a pre-supplementation test visit,
28 days of daily supplementation, and a post-
supplementation test visit. During the testing visits, the
subjects performed the fatigue test of Thorstensson and
Karlsson [24] which consisted of 50 maximal, unilateral,
concentric, isokinetic leg extensions of the left leg at
180°·s− 1. After completion of the pre-supplementation test
visit, the subjects were randomly assigned to a supplemen-
tal group of phosphocreatine disodium salts plus blue-
berry extract (PCDSB; n = 11), an active control of
creatine monohydrate (CM; n = 12), or a placebo (n = 10).
The supplements were designed to be as similar as
possible in volume, color, and taste, and included 5.0 g
of phosphocreatine disodium salts plus 200 mg of blue-
berry extract in the PCDSB, 3.0 g of creatine
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monohydrate in the CM, and microcrystalline cellulose
in the placebo group. The 5.0 g of PCDSB was 50% pure
creatine and, therefore, each dose of the PCDSB con-
tained 2.5 g of pure creatine. The 3.0 g of CM was 80%
pure creatine and contained 2.4 g of pure creatine per
dose. The blueberry extract was prepared from Vacci-
nium angustifolium berries and was standardized to 30%
total phenols using the Follin-C assay. Thus, the 200mg
of blueberry extract in the PCDSB included 60mg of
phenols which consisted of a majority of proanthocyanins
and a minority of anthocyanins. The bulk powder
mixtures were sieved through a 60-mesh sieve to ensure
uniform particle size and to get rid of the agglomerates.
They were further blended for 1 h using an Erweka
V-mixer (Model AR 403, Erweka America Inc., Edison,
NJ) prior to packaging. Homogeneity of mixing was
visually confirmed with the coloring agents used.
Blended powders were accurately weighed (mass ± 1%)
into individual foil lined pouches using a calibrated
balance (Model SX 410, Denver Instruments, Bohe-
mia, NY) and heat sealed. Five quality control sam-
ples were randomly selected from the packaged batch
throughout the packaging process to ensure even dis-
tribution of contents, verified by mass for all samples
and for creatine content in samples containing either
PCDSB or CM by HPLC analysis. The HPLC method
used was previously developed and validated per USP
standards for accuracy, precision, and detection/quan-
titation limits. Samples were run on a Waters Acquity
H-Class UPLC (Waters Inc. Framingham, MA) equipped
with a photodiode array, column oven, and refrigerated
autosampler. Creatine and creatinine peaks were sepa-
rated using a 250 mm× 4.6 mm 5 μm Agilent ZORBAX
Eclipse XDB-C18 base deactivated C18 column with a
mobile phase consisting of 0.05M ammonium sulfate
at a flow rate of 1.5 ml/min and a temperature of
60 °C. Detection of standards and samples was per-
formed at 206 nm using a photodiode array. All of the
ingredients utilized in this study were supplied by Phe-
nolics LLC (Omaha, NE). The subjects were provided
with 28 days of individually packaged packets of pow-
der of their assigned supplement and were instructed
to mix the contents of the packet with 8 oz. of water
and drink it immediately after mixing. Twenty-eight
days of supplementation was based on the findings of
Hultman et al. [14] who reported that 3.0 g·d− 1 of
CM for 28 days resulted in approximately the same
20% increase in muscle total creatine concentration as
loading with 20 g·d− 1 for 6 days. The subjects were
instructed to maintain their usual exercise and dietary
habits throughout the study. Each subject completed
a 3-day dietary recall form and a 7-day exercise recall form
prior to the pre-supplementation testing visit and prior to
the post-supplementation testing visit to determine if
there were changes in total caloric and macronutrient
(carbohydrate, protein, and fat) intake as well as exercise
(aerobic and resistance training) time during the supple-
mentation period.
Subjects
Thirty-three men volunteered to participate in this study
(Table 1). Prior to testing, the subjects were screened for
any medications, dietary supplements, nutritional prod-
ucts, or dietary programs that would potentially con-
found the results of this study. Additionally, the subjects
reported no cardiovascular, metabolic, pulmonary, or
musculoskeletal diseases. All subjects signed a written
Informed Consent and completed a Health History
Questionnaire that were approved by the Institutional
Review Board for Human Subjects at the University of
Nebraska-Lincoln (IRB #20200319941FB).
Familiarization visit
The first visit served as an orientation for the subjects to
become familiar with the testing procedures to be com-
pleted during the subsequent test visits. During this visit,
the subjects performed submaximal and maximal isokin-
etic leg extensions of the left leg at 180°·s− 1 on a cali-
brated Cybex II isokinetic dynamometer (Lumex Inc.,
Bay Shore, NY, USA). At the end of the familiarization
visit, the subjects were asked to complete a 3-day dietary
recall form and a 7-day exercise recall form by the day
of the subsequent test visit and to abstain from exercise
24 h prior to the test visit.
Test visits
Prior to testing, all subjects returned their completed 3-
day dietary recall form and 7-day exercise recall form.
The subjects performed a standardized warm-up consist-
ing of 5 min of cycle ergometry at 50W (Ergomedic
828E, Monark, Varberg, Sweden). The subjects were
then seated on the isokinetic dynamometer with the
head of the dynamometer aligned with the axis of rota-
tion of the left knee. The distal portion of the lever arm
of the dynamometer was affixed to the left ankle with a
Velcro strap according to the manufacturer’s recommen-
dations [25]. The subjects then completed the fatigue
test, consisting of 50 maximal, unilateral, concentric, iso-
kinetic leg extensions at 180°·s− 1. The investigators pro-
vided verbal encouragement throughout the test. For all
isokinetic repetitions in the present study, the damping
of the Cybex II was set at 2.
Supplementation
Following the pre-supplementation fatigue test, the sub-
jects were provided with 28 days of individually packaged
powder of their assigned supplement. Investigators con-
tacted each subject on a weekly basis to promote
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adherence and to ensure that the subjects experienced
no adverse or serious adverse events related to the sup-
plementation protocol. Five days prior to completion of
the supplementation period, investigators scheduled the
subjects for their post-supplementation test visit,
instructed the subjects to complete a second 3-day diet-
ary recall form and 7-day exercise recall form before the
test visit, and reminded the subjects to abstain from ex-
ercise 24 h prior to the test visit.
Determination of peak torque, average power, and
percent decline
For the pre-supplementation and post-supplementation
test visits, peak torque (PT) and average power (AP)
were assessed during the fatigue test. Peak torque and
AP were defined as the mean values from the first three
repetitions of the fatigue test [24]. Average power was
operationally defined in the as the time averaged, inte-
grated area under the isokinetic torque curve. To calcu-
late the AP, the voltage-time relationships from the
Cybex II strip chart output was converted to the isokin-
etic torque curve by converting the voltage to torque in
N·m based on a regression equation developed from the
Cybex II calibration procedures recommended by the
manufacturer [25]. Integration of the area under the
torque curve was accomplished using a custom Lab-
VIEW program (National Instrument, Austin, TX, USA)
and the AP was then calculated by dividing the inte-
grated area under the torque curve by the time for each
isokinetic repetition. Percent decline across the fatigue
test were calculated for peak toque (PT%) and average
power (AP%) as:
Percent Decline ¼ ½ Mean of First 3 Repetitions−Mean of Last 3 Repetitionsð Þ
 Mean of First 3 Repetitions   100
Statistical analyses
Test-retest reliability for PT and AT for the placebo
group were measured 28 days apart and assessed with a
repeated measures ANOVA (2,1 model) to determine
systematic error, the interclass correlation coefficient
(ICC) and the standard error of measurement (SEM)
[26]. Peak torque, AP, PT%, and AP% were analyzed
using 3 (Group [PCDSB, CM, and placebo]) × 2 (Time
[Pre-supplementation and post-supplementation]) mixed
factorial ANOVAs and paired t-tests were used for a
priori, planned comparisons across the 28 days of sup-
plementation within each group [27]. To determine im-
portant changes in PT and AP for individual subjects,
the minimal important difference (MID) values were cal-
culated as [28]:
MID ¼ SDpooled  0:5
Where SDpooled was the pre-supplementation between-
subjects standard deviation and 0.5 reflects a moderate
effect size necessary to be considered an important
change [28]. The proportion of subjects that exceeded
the MID for PT, AT, PT%, and AP% were examined be-
tween each group using separate Chi-squared (χ2) tests.
Total calories, carbohydrate, protein, and fat intake as
well as aerobic exercise, resistance training exercise, and
total exercise time from pre- and post-supplementation
were assessed with separate 3 (Group [PCDSB, CM, and
placebo]) × 2 (Time [Pre-supplementation and post-
supplementation]) mixed factorial ANOVAs. Partial eta
squared (η2p) and Cohen’s d were calculated for each re-
peated measures ANOVA and pairwise comparison, re-
spectively, and an alpha of p < 0.05 was considered
statistically significant. All statistical analyses were per-
formed using IBM SPSS v 27 (Armonk, NY, USA).
Results
Test-retest reliability
The test-retest reliability for PT and AP measured pre-
and post-supplementation for the placebo group (n = 10)
were examined for mean differences (systematic error),
ICCs, and SEM using the 2,1 model of Weir [26]. The
results demonstrated no significant mean differences











Age (years) 19.8 ± 1.1 20.3 ± 0.9 20.6 ± 1.2 20.2 ± 1.1




85.7 ± 21.4 89.6 ± 12.6 80.8 ± 11.9 85.5 ± 16.1
Post-
Supplementation
86.4 ± 21.1 89.8 ± 12.9 80.6 ± 11.7 85.8 ± 16.1
Note: There was no significant interaction (p = 0.433, η2p = 0.054) or main effect for Time (p = 0.409, η
2
p = 0.023) or Group (p = 0.450, η
2
p = 0.052) for body mass
across 28 days of supplementation
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between pre-supplementation and post-supplementation
for PT (99.82 ± 36.51 N·m vs 107.52 ± 44.11 N·m; p =
0.122, η2p = 0.256) or AP (141.94 ± 51.92W vs 150.79 ±
64.30W; p = 0.279, η2p = 0.129; Table 2).
Dietary recall, exercise recall, and adverse events
During the 28 days of supplementation, there were no
adverse or serious adverse events and all subjects re-
ported consuming all daily doses of their supplement.
Analyses for the dietary intake demonstrated no signifi-
cant interactions (p = 0.160–0.400, η2p = 0.59–0.115) or
main effects for Time (p = 0.108–0.0.604, η2p = 0.009–
0.084) or Group (p = 0.537–0.7889, η2p = 0.016–0.038)
for total calories, carbohydrate, fat, or protein intake be-
fore and after the 28-day supplementation (Table 3).
Analyses for exercise participation demonstrated no sig-
nificant interactions (p = 0.116–0.395, η2p = 0.60–0.134)
or main effects for Time (p = 0.435–0.676, η2p = 0.006–
0.020) or Group (p = 0.248–0.856, η2p = 0.010–0.089)
for aerobic and resistance training, or total exercise
time from before to after the 28 days of supplementa-
tion (Table 3). Furthermore, there was no significant
interaction (p = 0.433, η2p = 0.054) or main effect for
Time (p = 0.409, η2p = 0.023) or Group (p = 0.450,
η2p = 0.052) for body mass across 28 days of supple-
mentation (Table 1).
Peak torque and average power
The results of the mixed factorial ANOVA for PT indi-
cated no significant interaction (p = 0.135, η2p = 0.125),
or main effect for Group (p = 0.900, η2p = 0.007), but
there was a significant main effect for Time (p < 0.001,
η2p = 0.520) where post-supplementation (113.04 ± 32.49
N·m) was significantly (p < 0.001, d = 0.44) greater than
pre-supplementation (99.89 ± 26.58 N·m). Planned pair-
wise comparisons demonstrated significant increases in
PT from pre- to post-supplementation for the PCDSB
group (99.90 ± 22.47 N·m vs 119.22 ± 29.87 N·m, p <
0.001, d = 0.73) and the CM group (99.95 ± 22.50 N·m vs
111.97 ± 24.50 N·m; p = 0.009, d = 0.51), but not for the
placebo group (99.82 ± 36.51 N·m vs 107.52 ± 44.11,
p = 0.112, d = 0.19; Table 4).
The results of the mixed factorial ANOVA for AP in-
dicated no significant interaction (p = 0.103, η2p = 0.141),
or main effect for Group (p = 0.891, η2p = 0.008), but
there was a significant main effect for Time (p < 0.001,
η2p = 0.428) where post-supplementation (160.51 ± 46.13
W) was significantly (p < 0.001, d = 0.44) greater than
pre-supplementation (141.85 ± 38.41W). Planned pair-
wise comparisons demonstrated significant increases in
AP from pre- to post-supplementation for the PCDSB
group (140.18 ± 32.08W vs 170.12 ± 42.68W, p < 0.001,
d = 0.79) and the CM group (143.42 ± 33.84W vs
159.78 ± 31.20W, p = 0.021, d = 0.50), but not for the
placebo group (141.94 ± 51.92W vs 150.79 ± 64.30W;
p = 0.279, d = 0.15; Table 4).
Percent change scores for peak torque and average
power
The results of the mixed factorial ANOVA for pre- ver-
sus post-supplementation PT% and AP% during the fa-
tigue test demonstrated no significant interactions (p =
0.270–0.432, η2p = 0.054–0.084), main effects for Time
(p = 0.080–0.251, η2p = 0.044–0.099), or main effects for
Group (p = 0.917–0.993, η2p = 0.001–0.006). Planned
pairwise comparisons demonstrated no significant (p >
0.05) differences between pre-supplementation and post-
supplementation for any of the groups (Table 5).
Minimal important difference for peak torque and
average power
The MID for PT was 13.29 N·m which was exceed by 8
of the 11 subjects (73%) for the PCDSB group, 7 of the
12 subjects (58%) for the CM group, and 2 of the 10
subjects (20%) for the placebo group (Table 6). The re-
sults of the χ2 analyses demonstrated that a significantly
(p = 0.016) greater proportion of subjects exceeded the
MID for the PCDSB group (73%) than the placebo group
(20%). There was no difference, however, in the propor-
tion of subjects exceeding the MID between the CM
group and placebo group (p = 0.069) or the PCDSB
group and the CM group (p = 0.469).
The MID for AP was 19.21W which was exceed by 7
of the 11 subjects (64%) for the PCDSB group, 8 of the
12 subjects (67%) for the CM group, and 4 of the 10
subjects (40%) for the placebo group (Table 7). The
results of the χ2 analyses indicated that there were no
significant differences (p > 0.05) in the proportion of
Table 2 Test-retest reliability of peak torque and average power from the placebo group (n = 10)
Visit 1 (Mean ± SD) Visit 2 (Mean ± SD) Grand Mean p-Value ICC ICC 95% CI SEM CV (%)
Peak Torque (N·m)
99.82 ± 36.51 107.52 ± 44.11 103.67 0.122 0.964 0.846–0.911 9.77 9.42
Average Power (Watts)
141.94 ± 51.92 150.79 ± 64.30 146.37 0.279 0.953 0.824–0.988 17.18 11.74
CV (%) coefficient of variation; ICC intraclass correlation coefficient; ICC 95% CI intraclass correlation coefficient 95% confidence interval; p-value type I error rate for
the one-way repeated measures ANOVA with a 2,1 model to assess systematic error, SEM standard error of measurement
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Table 3 Mean ± SD of dietary intake and exercise participation before and after 28 days of supplementation
Group Pre- Supplementation Post-Supplementation
Dietary Intake
Calories (kcals)
Creatine Monohydrate Group (n = 12) 1875.7 ± 656.2 1706.4 ± 581.5
Phosphocreatine Disodium Salts Plus Blueberry Extract Group (n = 11) 1704.8 ± 464.8 1781.7 ± 312.7
Placebo Group (n = 10) 1734.5 ± 377.3 1463.8 ± 223.4
Carbohydrates (g)
Creatine Monohydrate Group 173.4 ± 73.5 173.4 ± 70.4
Phosphocreatine Disodium Salts Plus Blueberry Extract Group 154.5 ± 67.0 161.3 ± 42.0
Placebo Group 187.1 ± 61.4 150.1 ± 36.7
Fats (g)
Creatine Monohydrate Group 73.6 ± 30.3 66.7 ± 25.2
Phosphocreatine Disodium Salts Plus Blueberry Extract Group 59.8 ± 23.0 66.0 ± 24.3
Placebo Group 64.6 ± 16.5 58.1 ± 18.4
Protein (g)
Creatine Monohydrate Group 100.5 ± 52.1 94.6 ± 35.3
Phosphocreatine Disodium Salts Plus Blueberry Extract Group 100.0 ± 473.7 107.7 ± 33.1
Placebo Group 99.4 ± 24.5 87.6 ± 23.2
Exercise Participation
Aerobic Training (hours/week)
Creatine Monohydrate Group 2.2 ± 2.3 1.7 ± 2.3
Phosphocreatine Disodium Salts Plus Blueberry Extract Group 0.9 ± 1.6 1.0 ± 1.5
Placebo Group 2.5 ± 2.2 2.7 ± 3.0
Resistance Training (hours/week)
Creatine Monohydrate Group 2.0 ± 1.6 3.4 ± 2.6
Phosphocreatine Disodium Salts Plus Blueberry Extract Group 3.2 ± 2.3 3.2 ± 2.1
Placebo Group 2.4 ± 1.7 2.0 ± 1.6
Total Exercise (hours/week)
Creatine Monohydrate Group 4.2 ± 3.0 5.0 ± 3.4
Phosphocreatine Disodium Salts Plus Blueberry Extract Group 4.2 ± 1.6 4.2 ± 1.7
Placebo Group 4.9 ± 2.3 4.6 ± 3.2
Note: Note: Analyses for the dietary intake demonstrated no significant interactions (p = 0.160–0.400, η2p = 0.59–0.115) or main effects for Time (p = 0.108–0.0.604,
η2p = 0.009–0.084) or Group (p = 0.537–0.7889, η
2
p = 0.016–0.038) for total calories, carbohydrate, fat, or protein intake before and after the 28-day
supplementation. Analyses for exercise participation also demonstrated no significant interactions (p = 0.116–0.395, η2p = 0.60–0.134) or main effects for Time (p =
0.435–0.676, η2p = 0.006–0.020) or Group (p = 0.248–0.856, η
2
p = 0.010–0.089) for aerobic and resistance training, or total exercise time
Table 4 Mean ± SD of peak torque and average power before and after 28 days of supplementation
Group Pre-Supplementation Post-Supplementation p-value Change (%)
Peak Torque (N·m)
Creatine Monohydrate Group (n = 12) 99.95 ± 22.50 111.97 ± 24.50* 0.009 10.47 ± 11.03
Phosphocreatine Disodium Salts Plus Blueberry Extract Group (n = 11) 99.90 ± 22.47 119.22 ± 29.87* < 0.001 14.74 ± 9.37
Placebo Group (n = 10) 99.82 ± 36.51 107.52 ± 44.11 0.112 4.43 ± 17.29
Average Power (Watts)
Creatine Monohydrate Group 143.42 ± 33.84 159.78 ± 31.20* 0.021 10.22 ± 13.62
Phosphocreatine Disodium Salts Plus Blueberry Extract Group 140.18 ± 32.08 170.12 ± 42.68* < 0.001 15.56 ± 13.05
Placebo Group 141.94 ± 51.92 150.79 ± 64.30 0.279 1.72 ± 21.95
* p < 0.05, post-supplementation > pre-supplementation
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subjects that exceeded the MID for any of the group
comparisons.
The MID for a reduction in the PT% from pre-
supplementation to post-supplementation was − 10.77%
which was exceeded by 1 of the 11 subjects (9%) for the
PCDSB group, 3 of the 12 subjects (25%) for the CM
group, and 2 of the 10 (20%) of subjects for the placebo
group (Table 8). The results of the χ2 analyses indicated
that there were no significant differences (p > 0.05) in
the proportion of subjects that exceeded the MID for
any of the group comparisons.
The MID for an improvement in AP% from pre-
supplementation to post-supplementation was − 10.51%
which was exceeded by 1 of the 11 subjects (9%) for the
PCDSB group, 1 of the 12 subjects (8%) for the CM
group, and 3 of the 10 (30%) of subjects for the placebo
group (Table 9). The results of the χ2 analyses indicated
that there were no significant differences (p > 0.05) in
the proportion of subjects that exceeded the MID for
any of the group comparisons.
Discussion
The purpose of the present study was to compare the ef-
fects of 28 days of supplementation with PCDSB, CM, or
placebo on measures of muscular strength, power, and
endurance. The reliability analyses (Table 2) for the pla-
cebo group across the 28 days of supplementation indi-
cated excellent reliability [29] for PT and AP with ICCs
of R = 0.9464 and R = 0.953, respectively. There was no
systematic error between the test and re-test assess-
ments as indicated by no mean differences (p = 0.122–
0.279) for PT or AP. These values were consistent with
previous studies of test-retest reliability for unilateral,
isokinetic leg extensions [30, 31]. The findings of the
Table 5 Mean ± SD of percent declines in peak torque and average power during the fatigue test before and after 28 days of
supplementation
Group Pre-Supplementation Post-Supplementation p-value
Peak Torque (%)
Creatine Monohydrate Group (n = 12) 40.30 ± 12.11 38.94 ± 18.36 0.780
Phosphocreatine Disodium Salts Plus Blueberry Extract Group (n = 11) 33.25 ± 31.39 43.69 ± 38.57 0.126
Placebo Group (n = 10) 38.00 ± 18.53 39.69 ± 25.65 0.728
Average Power (%)
Creatine Monohydrate 40.65 ± 12.25 45.91 ± 15.60 0.211
Phosphocreatine Disodium Salts Plus Blueberry Extract Group 35.41 ± 30.36 44.82 ± 42.38 0.104
Placebo 38.85 ± 18.55 39.19 ± 27.80 0.949
Table 6 Absolute change (post-supplementation – pre-supplementation) values for peak torque with identification of the individual
subjects that exceeded the minimal important difference
Creatine Monohydrate Group Peak Torque
Change (N·m)








Subject 1 14.45a 1 21.94a 1 25.53a
2 27.50a 2 16.64a 2 25.61a
3 15.01a 3 −3.31 3 9.19
4 16.64a 4 8.00 4 −22.38
5 −6.34 5 34.63a 5 4.24
6 2.06 6 18.51a 6 9.27
7 16.64a 7 8.80 7 −3.62
8 35.38a 8 28.07a 8 7.14
9 0.00 9 15.27a 9 8.94
10 −8.86 10 26.29a 10 13.04




7 of 12 (58%) 8 of 11 (73%) b 2 of 10 (20%)
aIndicates an increase in peak torque across the 28 days of supplementation that exceeded the minimal important difference (pooled pre-supplementation S.D. ×
0.5 effect size = 13.29 N·m). b Indicates a significantly (p < 0.05) greater proportion of individual subjects that exceeded the minimal important difference than the
placebo group as determined by χ2 analyses
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present study indicated that 28 days of supplementation
with PCDSB and CM resulted in comparable increases
in PT (14.74 ± 9.37% versus 10.47 ± 11.03%, respectively)
and AP (15.56 ± 13.05% versus 10.22 ± 13.62%, respect-
ively), but had no effects on fatigue-induced PT% and
AP%. It is possible that the effects of PCDSB and CM
supplementation on parameters associated with muscu-
lar endurance would have been better evaluated using
several repeated bouts of the fatigue tasks [32–34].
Creatine monohydrate is the most studied delivery
form for examining the effects of creatine supplementa-
tion on performance and served as the active control to
compare to PCDSB in this study. Previous studies [9, 35]
have reported that CM supplementation with 2.0–5.0
g·d− 1 for 28–30 days increased muscular strength,
power, and endurance. For example, Herda et al. [9] re-
ported that 30 days of CM supplementation at 5.0 g·d− 1
resulted in improvements for the countermovement
Table 7 Absolute change (post-supplementation – pre-supplementation) values for average power with identification of the
individual subjects that exceeded the minimal important difference
Creatine Monohydrate Group Average Power
Change (Watts)
Phosphocreatine Disodium Salts







Subject 1 20.17a 1 32.42a 1 40.02a
2 37.18a 2 14.97 2 37.06a
3 8.24 3 −9.32 3 22.53a
4 26.33a 4 7.44 4 −33.27
5 −27.68 5 53.58a 5 2.64
6 −0.16 6 29.08a 6 14.75
7 23.83a 7 10.43 7 −23.47
8 35.17a 8 40.69a 8 5.59
9 39.52a 9 45.09a 9 −3.55
10 −15.18 10 49.01a 10 26.23a




8 of 12 (67%) 7 of 11 (64%) 4 of 10 (40%)
aIndicates an increase in average power across the 28 days of supplementation that exceeded the minimal important difference (pooled pre-supplementation S.D.
× 0.5 effect size = 19.21 W)
Table 8 Differences in percent decline for peak torque (post-supplementation – pre-supplementation) during that fatigue test with
identification of the individual subjects that exceeded the minimal important difference
Creatine Monohydrate Group Peak Torque %
Decline Change
Phosphocreatine Disodium Salts







1 0.11 1 8.58 1 4.24
2 1.97 2 9.56 2 12.63
3 0.91 3 −29.01a 3 11.90
4 4.07 4 9.55 4 −26.67a
5 −20.67a 5 16.40 5 −0.99
6 2.75 6 55.55 6 −10.81a
7 −38.48a 7 −1.11 7 9.30
8 27.34 8 29.39 8 −9.62
9 0.00 9 8.88 9 0.81
10 7.75 10 9.37 10 26.07
11 10.53 11 −2.38
12 −12.62a
Proportion exceeding the minimal
important difference
3 of 12 (25%) 1 of 11 (9%) 2 of 10 (20%)
aIndicates a reduction in percent decline for peak torque that exceeded the minimal important difference (pooled pre-supplementation S.D. × 0.5
effect size = −10.77%)
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vertical jump, bench press 1RM, leg press 1RM, and the
number of repetitions to failure at 80% 1RM for bench
press and leg press. Their results [9] demonstrated that
the CM supplementation increased muscular power
(vertical jump), strength (bench press and leg press
1RM) and muscular endurance (repetitions to failure).
Furthermore, Brenner et al. [35] reported that CM sup-
plementation with 2.0 g·d− 1 for 28 days increased bench
press 1RM in women. Thus, the improvements in PT
and AP for the CM group, which served as the active
control group in the present study, were consistent with
previous studies that have demonstrated improvements
in muscular strength following 28–30 days of CM
supplementation.
Few studies [22, 36, 37] have examined the effects of
supplementation with phosphocreatine on exercise per-
formance outcomes. Peeters et al. [37] reported that
phosphocreatine supplementation with 20 g·d− 1 for 3
days followed by 10 g·d− 1 for the remainder of the 6
week supplementation period, along with a 4 day per
week of progressive, periodized resistance training pro-
gram, increased bench press 1RM by 8.8 kg, with no dif-
ference compared the CM supplementation (11.1 kg).
Eckerson et al. [22] found that 6 days of supplementation
with 5.0 g of CM plus 4.0 g of sodium and potassium
phosphates plus 18 g of dextrose increased anaerobic
work capacity from the critical power test by 23.8% at
day 3 and 49.8% at day 6, but CM supplementation and
the placebo did not. A subsequent 30 day trial of the
same supplement administered daily, however, showed
no change in anaerobic work capacity [36]. The results
of the present study extended these findings [22, 29, 38]
and suggested that phosphocreatine supplementation in
the form of PCDSB may be as effective in eliciting im-
provements in muscular strength as CM
supplementation.
The present study was designed to compare the effects
of 28 days of supplementation with PCDSB to an active
control of CM, and an inactive placebo of microcrystal-
line cellulose. The PCDSB and CM were manufactured
to contain a very similar amount of pure creatine. The
5.0 g of PCDSB was 50% pure creatine and, therefore,
each dose of the PCDSB contained 2.5 g of pure creatine.
The 3.0 g of CM was 80% pure creatine and contained
2.4 g of pure creatine per dose. Phosphocreatine diso-
dium salts were selected for use in the PCDSB, in part,
because of its greater solubility than CM and phospho-
creatine may increase the variety of delivery forms that
can be developed. Additionally, phosphocreatine diso-
dium salts may have a greater bioavailability compared
to CM and may saturate creatine stores at a faster rate,
resulting in faster adaptations to performance compared
to CM supplementation. The PCDSB contained sodium
and blueberry extract. The CM and placebo did not con-
tain sodium or blueberry extract and the PCDSB is a dis-
odium salt of phosphocreatine which contributes the
sodium during its absorption in the gastrointestinal
tract. Furthermore, sodium is an electrolyte that medi-
ates creatine transportation and aids in absorption and
utilization throughout the body [39, 40]. For example,
Peral et al. [6] examined the effects of sodium and chlor-
ide on creatine absorption in vitro and estimated that
two sodium molecules and one chloride molecule are
necessary for creatine transport. Furthermore, Dai et al.
Table 9 Differences in percent decline for average power (post-supplementation – pre-supplementation) during that fatigue test













1 0.07 1 11.37 1 6.64
2 5.16 2 9.15 2 10.17
3 0.17 3 −38.13a 3 11.39
4 6.49 4 14.25 4 −31.44a
5 −24.55a 5 18.79 5 −2.65
6 1.77 6 10.74 6 −13.68a
7 14.64 7 3.93 7 11.36
8 27.96 8 30.52 8 −12.37a
9 23.68 9 21.32 9 −0.97
10 6.81 10 5.80 10 24.92




1 of 12 (8%) 1 of 11 (9%) 3 of 10 (30%)
aIndicates a reduction in percent decline for average power that exceeded the minimal important difference (pooled pre-supplementation S.D. × 0.5
effect size = −10.51%)
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[41] reported that increased sodium concentration in an
extracellular fluid enhanced creatine uptake in vitro.
Thus, the mechanisms proposed by Peral et al. [6] and
Dai et al. [41] suggest that the sodium content of PCDSB
may function to facilitate greater creatine transporter
function, resulting in a greater creatine absorption.
The blueberry extract in the PCDSB is rich in polyphe-
nols including proanthocyanins and anthocyanins which
exhibit antioxidant [19] and anti-inflammatory [42]
properties and enhanced blood flow [43]. Evidence re-
garding the use of antioxidants have reported equivocal
reports, including studies suggesting that antioxidants
may blunt cellular mechanisms associated with adapta-
tion and recovery [44, 45]. Antioxidant supplementation,
however, has been demonstrated to improve strength
[23, 46] and power [47], as well as delay the effects of fa-
tigue [23, 48] and enhance recovery following eccentric-
ally induced muscle damage [49]. Thus, theoretically, the
blend of phosphocreatine, blueberry extract, and sodium
may have had synergistic effects that resulted in signifi-
cant improvements in exercise performance.
Some individuals respond to creatine supplementation
with increases in muscle phosphocreatine stores and
strength, while others do not [50]. Greenhaff et al. [51]
suggested that 20–30% of individuals who underwent 5
days of creatine loading with 20 g·d− 1 “did not respond”
based on an increase in total creatine of less than 10
mmol·kg− 1 dry weight. Syrotuik and Bell [50] reported
that “responders” increased incline leg press 1RM by
25.8 kg following 5 days of creatine loading with approxi-
mately a mean of 23 g·d− 1 (0.3 g·kg− 1·d− 1), while the
non-responders increased only by 2.0 kg. In the present
study, the responses of the individual subjects were
judged based on an MID that corresponded to a stan-
dardized effect size of 0.5 times the pre-supplementation
pooled standard deviation [28, 38, 52]. For PT (Table 6),
the PCDSB group exhibited a greater proportion (73%)
of individual subjects who demonstrated increases across
the 28 days of supplementation that exceeded the MID
than the placebo group (20%). The proportion of indi-
vidual subjects that exceeded the MID values for the
CM group for PT (58%), however, was not significantly
greater than the placebo group. Thus, when compared
to the placebo group, supplementation with the blend of
PCDSB provided an advantage over CM for the PT re-
sponses of the individual subjects. There were no differ-
ences in the proportions of individual subjects in the
PCDSB, CM, and placebo groups that exceeded the MID
for AP (Table 7), PT% (Table 8), or AP% (Table 9). For
PT% and AP%, the proportions of individual subjects
that exceeded the MID was less than or equal to 30%.
The lack of adverse and serious adverse events during
the course of this study for the PCDSB, CM, and placebo
groups were consistent with the safety of creatine
supplementation [2, 3]. Furthermore, the results indi-
cated that there were no significant (p > 0.05) mean dif-
ferences between the PCDSB, CM, and placebo groups
or changes across the 28 days of supplementation for
body mass, total caloric intake, macronutrient intake,
weekly aerobic training, weekly resistance training, or
total weekly exercise (Tables 1 and 3). Thus, the 28 days
of supplementation with PCDSB or CM had no effect on
body mass. These findings were consistent with a previ-
ous study by Camic et al. [11] who reported no change
in body mass across a 28 day supplementation period
with polyethylene glycosylated (PEG) creatine. A subse-
quent study by Camic et al. [12], however, reported a
significant 1.1 to 1.7% increase in body mass across 28
days of PEG creatine supplementation and Herda et al.
[9] reported significant 0.4–1.0 kg increases in body
mass following 30 days of CM and PEG creatine supple-
mentation. Furthermore, Eckerson et al. [36] found a
significant 1.0 kg increase in body mass following 30 days
of supplementation with a blend of creatine, sodium, po-
tassium, and dextrose.
The mean values for the dietary intake parameters in
the present study were similar to those from recent
studies [23, 53], but somewhat lower than expected for
this sample [54]. This was likely due to the systematic
underreporting of nutritional intake from the dietary re-
call form [55]. None of the subjects in the present study
were competitive athletes, and the 7-day exercise recall
indicated that they were recreationally trained [56].
Limitations in the present study include that the sub-
jects did not return used supplement packets, but pro-
vided verbal confirmation that all packets had been
consumed. While there was no significant Group by
Time interaction for the repeated measures ANOVAS
for PT and AP, the study was designed with a priori
planned comparisons across Time within each supple-
ment group, as well as the examination of the individual
responses to supplementation. No blood or urine was
collected to examine direct or indirect changes in intra-
muscular creatine stores throughout the supplementa-
tion. It has previously been demonstrated, however, that
supplementation with 3 g/day of creatine monohydrate
for 28 days significantly increased muscle total creatine
concentrations by 20mmol [14]. Furthermore, the sup-
plementation of 5 g/day is consistent with the recom-
mendations of the International Society of Sports
Nutrition position stand on effective creatine dosing
strategies [2]. A limitation of the present study was that
the PCDSB included a blend of phosphocreatine, blue-
berry extract, and sodium. Thus, the positive effects of
PCDSB on muscular strength and power may have been
due to the additive effects of these ingredients. It was
not possible with this study design to determine the in-
dividual effects of phosphocreatine disodium salts or
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blueberry extract on the performance outcomes, or their
relative importance to the effects of PCDSB. Further-
more, like Herda et al. [9], the subjects in the present
study maintained their normal exercise habits through-
out the 28 days of supplementation. This methodology
has substantial ecological validity since consumers of
products like CM and PCDSB typically have a wide var-
iety of exercise habits. Additional control, however,
could be accomplished by including a prescribed exer-
cise program with the supplementation. Other aspects of
the current study design that should be further exam-
ined include the inclusion of female subjects and supple-
mentation with higher doses for shorter and/or longer
durations.
Conclusions
In summary, the result of the present study indicated
that 28 days of supplementation with PCDSB and CM
resulted in comparable mean increases in PT and AP.
There were no differences, however, for PT% and AP%
across the fatigue test from pre- to post-
supplementation for the PCDSB, CM, or placebo group.
Evaluation of individual responses showed that a larger
proportion of subjects exhibited increases in PT from
pre- to post-supplementation that were greater than the
MID values for the PCDSB group than the placebo
group. Overall, the current findings indicated that 28
days of supplementation with both PCDSB and CM re-
sulted in increases in PT and AP, however, there were
no mean differences between these groups as deter-
mined by repeated measures ANOVA.. The PCDSB,
however, may have an advantage over CM when com-
pared to the placebo group for the proportion of individ-
ual subjects that respond favorably to supplementation
with meaningful increases in muscular strength.
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